Drug Development in Psychiatry and Genomics: From E. Coli to Man
Author:
- 1 November 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 7 (6) , 415-419
Abstract
In the last column, the paradigm of anti-infective drug development and its application to psychiatric drug development was discussed. Protease inhibitors were used to illustrate how drug development can be targeted to specific sites of action. Azole antifungals were used to illustrate how unintended affects can be produced due to the fact that even yeast and man share some genetic similarities. This column will continue this theme by discussing how the knowledge gained from the sequencing of the Escherichia coli (E. coli) genome is likely to affect psychiatric drug development. The column will also expand the discussion begun in the last column concerning the greater challenges encountered in developing drugs to treat psychiatric illnesses versus infectious diseases (Table 1), even while acknowledging the commonality between these two development processes. Understanding these challenges is conceptually important for both the prescriber and the researcher. This knowledge provides a context for understanding the limitations of current psychiatric drug development as well as how the human genome project will likely change this process in the future. To paraphrase Steinbeck, this column could be entitled “Of E. coli and men.” The number of genes in the human genome has still not been determined with certainty; however, the latest best estimates are 40,000–50,000 genes. In contrast, the E. coli genome contains approximately ten times fewer genes: 4,401. 1 Yet, the sequencing of the complete genome for this organism, which was first accomplished in 1997 by two different groups of scientists, 2,3 has considerable import for our understanding of the cellular paradigm (i.e., the mechanisms of life at a cellular level) and, hence, for drug development in psychiatry. The importance of E. coli was underscored by Schaechter and Neidhart, who stated: “All cell biologists have two cells of interest: the one they are studying and Escherichia coli.”4 This is true even for the cell biologist interested in brain function, even though all the cells in even the most primitive brains are eukarocytes (i.e., have a true nucleus bounded by a membrane), whereas E.coli is a prokarocyte (i.e., an organism with its DNA or nuclear material scattered in the cytoplasm of the cell but that nevertheless reproduces by cell division). The E. coli cell achieved its vaunted position in the late 1930s when the forefathers of modern cell biology concluded that it was only by elucidating the simplest biological systems that the relationship between genes and cell function could be understood. The goal was to understand the logic of life based on the concept that the mechanisms of life are finite, tractable, and subject to full exploration and understanding. The E. coli cell became a cornerstone in this undertaking for a number of reasons. 4,5 Its simple nutritional requirements meant that it could be isolated and grown relatively easily in the laboratory. A new generation was produced every 20 minutes, a feature that allowed study of the effects of mutations on the synthesis or use of essential metabolites. It was generally well behaved, with a low risk of pathogenicity, making it relatively safe for laboratory study. It was a sexual organism in that it demonstrated the ability for genetic recombination between cells. All of these features facilitated study of the linkage between biochemistry and genes. As a result of the extensive study of E. coli during the last 60–70 years of the 20th century, more was (and probably still is) known about the biochemistry of E. coli than of any other living organism by the time its genome was sequenced. E.Keywords
This publication has 12 references indexed in Scilit:
- Drug Development in Psychiatry and the Human Genome Project: The Explosion in Knowledge and Potential TargetsJournal of Psychiatric Practice, 2001
- Antipsychotic Drug Development in the Pre-Human-Genome Era: A Full CircleJournal of Psychiatric Practice, 2001
- Compilation of DNA sequences of Escherichia coli K12: description of the interactive databases ECD and ECDCNucleic Acids Research, 1998
- The Escherichia coli genome sequence: the end of an era or the start of the FUN?Molecular Microbiology, 1997
- The Complete Genome Sequence of Escherichia coli K-12Science, 1997
- EcoCyc: Enyclopedia of Escherichia coli Genes and MetabolismNucleic Acids Research, 1997
- Construction of a Contiguous 874-kb Sequence of the Escherichia coli-K12 Genome Corresponding to 50.0-68.8 min on the Linkage Map and Analysis of Its Sequence FeaturesDNA Research, 1997
- The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed OutpatientsAnnals of Clinical Psychiatry, 1996
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960